Drugs / VP-315
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05188729 | Feb 2022 → Apr 2024 | skin basal cell carcinoma | Verrica Pharmaceuticals Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Lytix Biopharma AS | Results New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma oslobors.no ↗
The data suggests a potential abscopal effect of VP-315 in the treatment of basal cell carcinoma (BCC), as evidenced by reductions in the size of untreated, non-injected lesions. |
| 2026-05-05 | Verrica Pharmaceuticals Inc. | Results Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting verrica.com ↗
The peripheral anticancer activity we are observing well beyond the injection site suggests that VP-315 could be exerting an abscopal effect for the treatment of basal cell carcinoma,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. |
| 2025-11-10 | Lytix Biopharma AS | Results New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide oslobors.no ↗
The immunological analyses from Verrica’s Phase II study in basal cell carcinoma (BCC) demonstrated strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, alongside a marked reduction in immunosuppressive T-regulatory cells in the tumor microenvironment. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05188729 ↗ |
| Route | Other | “administered via intratumor injection into a single target lesion” NCT05188729 ↗ |